Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Enterprise Value (2016 - 2025)

Sutro Biopharma's Enterprise Value history spans 10 years, with the latest figure at -$167.6 million for Q3 2025.

  • For Q3 2025, Enterprise Value rose 56.83% year-over-year to -$167.6 million; the TTM value through Sep 2025 reached -$167.6 million, up 56.83%, while the annual FY2024 figure was -$316.9 million, 184.96% down from the prior year.
  • Enterprise Value for Q3 2025 was -$167.6 million at Sutro Biopharma, up from -$205.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$66.6 million in Q1 2022 and bottomed at -$388.3 million in Q3 2024.
  • The 5-year median for Enterprise Value is -$191.6 million (2022), against an average of -$197.6 million.
  • The largest annual shift saw Enterprise Value soared 79.3% in 2021 before it tumbled 347.29% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$67.6 million in 2021, then crashed by 347.29% to -$302.3 million in 2022, then skyrocketed by 63.22% to -$111.2 million in 2023, then crashed by 184.96% to -$316.9 million in 2024, then soared by 47.11% to -$167.6 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Enterprise Value are -$167.6 million (Q3 2025), -$205.1 million (Q2 2025), and -$249.0 million (Q1 2025).